CURE staff

Patients with advanced melanoma experienced high response rates when treated with commercial Amtagvi in a real-world clinical study.

The FDA has granted orphan drug designation to zenocutuzumab-zbco for the treatment of adults with advanced unresectable or metastatic cholangiocarcinoma.

The U.S. FDA has issued an updated safety communication regarding two commonly used chemotherapy drugs, Xeloda and fluorouracil.

Ampligen and Imfinzi combination therapy demonstrated clinical activity for patients with metastatic pancreatic cancer.

NCCN Guidelines now recommend Trodelvy as a category 1 first-line option for PD-L1–negative metastatic TNBC following phase 3 trial results.

The U.S. FDA has granted fast track status to pelareorep combination therapy for some KRAS-mutant, microsatellite-stable metastatic colorectal cancers.

The FDA granted Breakthrough Therapy status to zovegalisib plus Faslodex for patients with PIK3CA-mutated HR+/HER2- advanced breast cancer.

Quest Diagnostics debuts a new blood test for myeloma MRD, offering NGS-level sensitivity and a less invasive alternative to bone marrow biopsies.

The FDA cleared a phase 3 trial for iSCIB1+ after data showed 74% progression-free survival at 16 months for patients with advanced melanoma.

The FDA accepted a supplemental biologics license application and granted priority review for Datroway for adults unresectable or metastatic triple-negative breast cancer who are not candidates for PD-1/PD-L1 inhibitor therapy.

The FDA accepted a new drug application for zanzalintinib plus immunotherapy after showing improved survival in some previously treated colorectal cancers.

A study found that a blood test detecting ctDNA after surgery more accurately predicts recurrence and survival in patients with stage 3 colon cancer.

A real-world study found Erleada reduced the risk of death compared with Nubeqa in patients with metastatic castration-sensitive prostate cancer.

Clinical trial data shows that the protein CD47 may predict how well evorpacept works for patients with metastatic breast cancer.

The FDA has granted orphan drug designation to IFx-2.0 for patients with stage 2B to stage 4 cutaneous melanoma.

Biotin supplements used for cancer-related hair loss may interfere with key blood tests, risking inaccurate results and altered care decisions.

Adding Ibrance to maintenance therapy extends the time some patients with metastatic breast cancer live without their disease progressing.

Researchers have revealed how patients with metastatic breast cancer develop resistance to Enhertu treatment.

Researchers found that nearly two-thirds of patients with HER2-positive metastatic breast cancer did not receive the guideline-recommended standard of care treatment.

The FDA has granted fast track designation to LBL-034 for patients with relapsed or refractory multiple myeloma.

The FDA approved a larger nelarabine vial to improve dosing flexibility and simplify treatment for adult and pediatric patients with T-ALL and T-LBL.

A phase 2 trial showed onvansertib plus FOLFIRI and Avastin improved response and disease control in first-line RAS-mutated metastatic colorectal cancer.

The FDA granted orphan drug designation to CTD402 for relapsed or refractory T-cell acute lymphoblastic leukemia and lymphoblastic lymphoma.

The NCCN Clinical Practice Guidelines in Oncology now include Besremi as a Category 1 preferred treatment option for some with high-risk essential thrombocythemia.

The FDA granted breakthrough therapy designation to bezuclastinib plus Sutent for patients with gastrointestinal stromal tumors following progression.

The FDA granted fast track designation to IBI3003 for patients with relapsed/refractory multiple myeloma after receiving four-plus lines of therapy.

The FDA cleared a phase 3 trial of iSCIB1+ for advanced melanoma after phase 2 data showed improved progression free survival versus standard care.

Learn about large cell lung cancer, from diagnosis to stage-specific treatments, side effects and care options to guide patients through their journey.

The FDA granted fast track designation to Enolen for patients with low-to-intermediate risk prostate cancer.

FDA granted breakthrough therapy designation to zoldonrasib for previously treated KRAS G12D-mutated non-small cell lung cancer.